{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03479671",
            "orgStudyIdInfo": {
                "id": "831425"
            },
            "organization": {
                "fullName": "University of Pennsylvania",
                "class": "OTHER"
            },
            "briefTitle": "Low Dose Fat-Induced Insulin Resistance",
            "officialTitle": "A Dose Finding Study for Fat-Induced Insulin Resistance in Healthy Volunteers",
            "acronym": "BCAA",
            "therapeuticArea": [
                "Endocrinology",
                "Other"
            ],
            "study": "low-dose-fat-induced-insulin-resistance"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-01-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-03-20",
            "studyFirstSubmitQcDate": "2018-03-20",
            "studyFirstPostDateStruct": {
                "date": "2018-03-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Zoltan Arany",
                "investigatorTitle": "Associate Professor Of Medicine",
                "investigatorAffiliation": "University of Pennsylvania"
            },
            "leadSponsor": {
                "name": "University of Pennsylvania",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary goal of this study is to determine the dose of fatty acids that acutely induces mild insulin resistance in healthy volunteers. We hypothesize that a low-dose of fatty acid infusion (Intralipid/heparin) will cause a mild insulin resistance. The dose of fatty acid infusion that reliably causes mild insulin resistance will be selected for use in future studies.",
            "detailedDescription": "This study is designed to test the hypothesis that a low-dose of fatty acid infusion (Intralipid/heparin) will cause mild insulin resistance. This dose-finding study is critical for future studies on free-fatty acid induced insulin resistance.\n\nHealthy male and healthy female volunteers will undergo a 6 hour hyperinsulinemic-euglycemic clamp, in order to establish insulin sensitivity parameters in the presence of fatty acid co-infusion. The subjects will then return 1-3 weeks later, and undergo another 6 hour HIE clamp, this time in the presence of low-dose fatty acid co-infusion (30ml/hr). If this dose does not achieve \\~25% reduction in the rate of glucose disposal, then the dose-confirmation study will be repeated 1-3 weeks later with a medium-dose fatty acid co-infusion (60ml/hr).\n\nA dose-response effect of fatty acids on insulin resistance has been demonstrated before, but not in the precise conditions of our study. This dose-finding study is critical because future studies require a reliable dose of fatty acid infusion, and the exact dose of fatty acid infusion that causes mild insulin resistance may be different in the conditions of our study."
        },
        "conditionsModule": {
            "conditions": [
                "Diabetes Mellitus, Type 2",
                "Insulin Resistance",
                "Insulin Sensitivity"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Baseline insulin sensitivity will be measured in healthy volunteers, and then 1-3 weeks later insulin sensitivity will be measured in response to a low-dose fatty acid infusion. If there is no response to this low-dose infusion, then 1-3 weeks later insulin sensitivity will be measured in response to a medium-dose fatty acid infusion.",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Saline",
                    "type": "NO_INTERVENTION",
                    "description": "Insulin sensitivity (rate of glucose disposal)"
                },
                {
                    "label": "Low Dose Fatty Acids",
                    "type": "EXPERIMENTAL",
                    "description": "Insulin sensitivity (rate of glucose disposal) in response to 30 ml/hr fatty acid infusion",
                    "interventionNames": [
                        "Drug: Intralipid, 20% Intravenous Emulsion"
                    ]
                },
                {
                    "label": "Medium Dose Fatty Acids",
                    "type": "EXPERIMENTAL",
                    "description": "Insulin sensitivity (rate of glucose disposal) in response to 60 ml/hr fatty acid infusion",
                    "interventionNames": [
                        "Drug: Intralipid, 20% Intravenous Emulsion"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Intralipid, 20% Intravenous Emulsion",
                    "description": "Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)",
                    "armGroupLabels": [
                        "Low Dose Fatty Acids",
                        "Medium Dose Fatty Acids"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Insulin Sensitivity",
                    "description": "Rate of Glucose Disposal (mg/kg/min)",
                    "timeFrame": "6 hours"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects who are able to provide written informed consent and to comply with the procedures of the study protocol\n\nExclusion Criteria:\n\n* History of diabetes\n* History of diabetes in more than one first-degree relative\n* Body mass index (BMI) \\<19 or \\>27 kg/m2\n* HbA1c \\>5.7%\n* Blood Pressure: systolic \\>160 mmHg or diastolic \\> 100 mmHg\n* Baseline hemoglobin concentration \\< 11 g/dl in women and \\< 12 g/dl in men\n* Estimated glomerular filtration rate \\< 55 ml/min/1.73 m2 (calculated using the subject's measured serum creatinine and the Modification of Diet in Renal Disease \\[MDRD\\] study estimation formula).\n* Presence of soy or egg allergies (due to possible reactions with fat infusate)\n* For female participants: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study. Oral contraceptives, Norplant\u00ae, Depo-Provera\u00ae, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable.\n* Known active alcohol or substance abuse\n* Use of tobacco within the previous year\n* Severe co-existing cardiac disease, characterized by any one of these conditions:\n\n  1. history of myocardial infarction within past 6 months;\n  2. history of ischemia on functional cardiac exam within the last year;\n  3. history of left ventricular ejection fraction \\< 30%.\n* Persistent elevation of liver function tests \\> 1.5 times normal upper limits\n* Hyperlipidemia (fasting LDL cholesterol \\> 130 mg/dl, treated or untreated; and/or fasting triglycerides \\> 200 mg/dl)\n* Receiving treatment for a medical condition requiring chronic use of systemic steroids, except for the use of \u2264 5 mg prednisone daily, or an equivalent physiological dose of hydrocortisone\n* Presence of a seizure disorder\n* Use of any investigational agents within 4 weeks of enrollment\n* Any medical condition, which in the opinion of the investigator, will interfere with the safe completion of the study\n* History of pancreatitis\n* Presence of a metal allergy (aluminum)",
            "healthyVolunteers": true,
            "sex": "ALL",
            "genderBased": true,
            "genderDescription": "Male or Female at birth.",
            "minimumAge": "18 Years",
            "maximumAge": "44 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Paola Alvarado, MS",
                    "role": "CONTACT",
                    "phone": "215-746-2081",
                    "email": "Paola.Alvarado@Pennmedicine.upenn.edu"
                },
                {
                    "name": "Michael D Neinast, BS",
                    "role": "CONTACT",
                    "phone": "469-323-7470",
                    "email": "mneinast@pennmedicine.upenn.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Zoltan P Arany, MD, PhD",
                    "affiliation": "Associate Professor of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Paola Alvarado, B.S.",
                            "role": "CONTACT",
                            "phone": "215-746-2081",
                            "email": "Paola.Alvarado@Pennmedicine.upenn.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003924",
                    "term": "Diabetes Mellitus, Type 2"
                },
                {
                    "id": "D000007333",
                    "term": "Insulin Resistance"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000006946",
                    "term": "Hyperinsulinism"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7119",
                    "name": "Diabetes Mellitus, Type 2",
                    "asFound": "Diabetes Mellitus, Type 2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M10370",
                    "name": "Insulin Resistance",
                    "asFound": "Insulin Resistance",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9997",
                    "name": "Hyperinsulinism",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000545823",
                    "term": "Soybean oil, phospholipid emulsion"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005217",
                    "term": "Fat Emulsions, Intravenous"
                },
                {
                    "id": "D000057947",
                    "term": "Parenteral Nutrition Solutions"
                },
                {
                    "id": "D000019999",
                    "term": "Pharmaceutical Solutions"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "relevance": "LOW"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                },
                {
                    "id": "M223889",
                    "name": "Soybean oil, phospholipid emulsion",
                    "asFound": "Conversion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8360",
                    "name": "Fat Emulsions, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M28934",
                    "name": "Parenteral Nutrition Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "T294",
                    "name": "Soy Bean",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "HB",
                    "name": "Herbal and Botanical"
                }
            ]
        }
    },
    "hasResults": false
}